Coronary Artery Disease
Systemic rapamycin to prevent restenosis: A glimpse to the past?†
Jorge Belardi MD, FACC, FSCAI,
Corresponding Author
Jorge Belardi MD, FACC, FSCAI
Department of Interventional Cardiology and Endovascular Therapeutics, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
Blanco Encalada 1543, Buenos Aires, capital federal, Argentina 1428
Search for more papers by this author
Jorge Belardi MD, FACC, FSCAI,
Corresponding Author
Jorge Belardi MD, FACC, FSCAI
Department of Interventional Cardiology and Endovascular Therapeutics, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
Blanco Encalada 1543, Buenos Aires, capital federal, Argentina 1428
Search for more papers by this author
First published: 16 February 2010
No abstract is available for this article.
REFERENCES
- 1
Douglas JSJr,Holmes DRJr,Kereiakes DJ,Grines CL,Block E,Ghazzal ZM,Morris DC,Liberman H,Parker K,Jurkovitz C, et al.
Coronary stent restenosis in patients treated with cilostazol.
Circulation
2005;
112:
2826–2832.
- 2
Tamhane U,Meier P,Chetcuti S,Chen KY,Rha SW,Grossman MP,Gurm H.
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: A meta-analysis of randomised controlled trials.
EuroIntervention
2009;
5:
384–393.
- 3
Versaci F,Gaspardone A,Tomai F,Ribichini F,Russo P,Proietti I,Ghini AS,Ferrero V,Chiariello L,Gioffre PA, et al.
Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study).
J Am Coll Cardiol
2002;
40:
1935–1942.
- 4
Brara PS,Moussavian M,Grise MA,Reilly JP,Fernandez M,Schatz RA,Teirstein PS.
Pilot trial of oral rapamycin for recalcitrant restenosis.
Circulation
2003;
107:
1722–1724.
- 5
Guarda E,Marchant E,Fajuri A,Martinez A,Moran S,Mendez M,Uriarte P. Valenzuela E,Lazen R.
Oral rapamycin to prevent human coronary stent restenosis: A pilot study.
Am Heart J
2004;
148:
e9.
- 6
Rodriguez AE,Granada JF,Rodriguez-Alemparte M,Vigo CF,Delgado J,Fernandez-Pereira C,Pocovi A,Rodriguez-Granillo AM,Schulz D,Raizner AE, et al.
Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: The prospective, randomized oral rapamycin in Argentina (ORAR II) study.
J Am Coll Cardiol
2006;
47:
1522–1529.
- 7
Waksman R,Ajani AE,Pichard AD,Torguson R,Pinnow E,Canos D,Satler LF,Kent KM,Kuchulakanti P,Pappas C, et al.
Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The oral rapamune to inhibit restenosis (ORBIT) study.
J Am Coll Cardiol
2004;
44:
1386–1392.
- 8
Stojkovic S, Ostojic M, Nedeljkovic M, et al.
Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation.
Catheter Cardiovasc Interv
2010; DOI 10.1002/ccd.22301.